bpc-157 human randomized controlled trials Pentadecapeptide BPC 157 (capitals) prevented muscle atrophy and BPC-157 as an Investigational Peptide
Description
For veterinary use only!
PARP1-mediated PPAR poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease
Treated mice showed increased proportions of larger, healthier muscle fibers and decreased intramyocellular lipid content, indicating enhanced fat oxidation capacity within muscle tissue
Substantial signals, unresolved in humans because the incentive to properly test them never existed
